Pharsight

Stivarga generic

Stivarga is a drug used to treat patients with gastrointestinal stromal tumor (GIST), including but not limited to patients previously treated with imatinib and patients with GIST resistant to a KIT tyrosine kinase inhibitor. The active ingredient in Stivarga is regorafenib. It was first authorised for market use on 27 September, 2012 and is owned by Bayer Healthcare. Stivarga has 5 drug patents, one of which has expired.

When will Stivarga generic be available?

Generics of Stivarga are expected to be released after 09 July, 2032, upon the expiration of the last patent. The patent expiry dates are important in determining the Stivarga generic release date.

Stivarga uses

Stivarga is primarily used in the treatment of patients with gastrointestinal stromal tumor (GIST). This includes patients who have previously been treated with imatinib, as well as those whose GIST is resistant to a KIT tyrosine kinase inhibitor. The efficacy of Stivarga comes from its active ingredient, regorafenib.

Stivarga patent expiration

Stivarga has 5 total drug patents, one of which has already expired. The remaining 4 patents protect Stivarga from generic competition until the last patent expires on 09 July, 2032. Below are the details of the patent:

EPO Oppostions filed on Stivarga

Litigations filed on Stivarga

Stivarga dosage

Want to ask something?